Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer
December 7th 2023Dr Abdou discusses how characteristics of patients with breast cancer impact ADC treatment selection and highlights some of the topline takeaways from breast cancer treatment to come out of the 2023 ASCO Annual Meeting.
Read More
FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
December 4th 2023Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how this regulatory decision increases the importance of multidisciplinary collaboration.
Read More
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
November 30th 2023Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.
Read More
Camidge and McVeigh Highlight the Role of the Clinical Geneticist Across Cancer Care and Research
November 27th 2023Drs Camidge and McVeigh highlight the evolution of the clinical genetics field over time, the process of identifying pathogenic genetic variants, the difficulties of explaining genetic testing results to patients, and more.
Read More
Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors
November 23rd 2023Dr Dumbrava discusses the rationale and design of the PYNNACLE trial; phase 1 efficacy and safety findings with PC14586 in patients with p53 Y220C–mutated advanced solid tumors; and the next steps for this research.
Read More
FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
November 20th 2023Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.
Read More
Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes
November 13th 2023Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on progression-free survival outcomes for patients with pancreatic cancer.
Read More
Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
November 9th 2023Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care, and the importance of confirming earlier post-hoc results from the VITAL trial in the AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.
Read More
FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
November 6th 2023Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.
Read More
Camidge and Garon Unpack Key Updates From the 2023 IASLC World Conference on Lung Cancer
November 2nd 2023In this episode of How This Is Building Me, Drs Camidge and Garon discuss the differences in lung cancer management and drug advancement between the United States and Asia and highlight other topline takeaways from the 2023 WCLC.
Read More
Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
October 30th 2023Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.
Read More
Naumann Discusses Notable Research Efforts in Endometrial Cancer
October 26th 2023Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUBY and NRG-GY018 trial regimens; and ongoing research that may elucidate optimal treatments for patients with recurrent, mismatch repair–deficient disease.
Read More
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
October 23rd 2023Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses.
Read More
New Data Bring Excitement, Raise Questions in Advanced RCC
October 16th 2023Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.
Read More
Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
October 12th 2023Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outpatient administration of this modality at John Theurer Cancer Center, and future considerations for using this treatment approach in solid tumors.
Read More
FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
October 5th 2023Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk myelodysplastic syndrome with anemia; key efficacy and safety data from the COMMANDS trial; and how this approval addresses historically unmet needs for this population.
Read More
Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
October 2nd 2023Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.
Read More
Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
September 28th 2023Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.
Read More
Multidisciplinary Approaches Shape Treatment Pathways in EGFR-Mutated NSCLC
September 26th 2023Emerging data in the neoadjuvant setting and the expansion of testing in standard practice have presented questions surrounding screening for and developing strategies from variant information in EGFR-mutated resectable non–small cell lung cancer.
Read More
Camidge and Garon Reflect on the Nuances of Career Development Through Clinical Research
September 25th 2023In this episode of How This Is Building Me, Drs Camidge and Garon discuss the importance of continuing to ask a variety of research questions throughout one’s career; the value of negative study results; and the ins and outs of running the lung cancer program and conducting phase 3 clinical trials at UCLA.
Read More
FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
September 21st 2023Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
Read More
Thoracic Clinical Expert Looks at Optimal Ways to Translate Data Into Practice
September 20th 2023As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.
Read More
Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm
September 19th 2023Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.
Read More
Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST
September 18th 2023Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.
Read More
Novel PROTAC May Usher in New Class of Drugs for ESR1+, ER+/HER2– Breast Cancer
September 18th 2023The development of novel next-generation hormonal agents is poised to change the landscape for patients with estrogen receptor-positive, HER2-negative breast cancer, offering additional oral solutions to lessen the burden of the invasive delivery of the standard of care and provide agents that are active against acquired variants.
Read More